Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and OpportunitiesMajed Ghattas, Mohamad‐Gabriel Alameh, Garima Dwivedi et al.|Vaccines|2021Cited by 227
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccinesXuexiang Han, Michael J. Mitchell, Ying Xu et al.|Nature Nanotechnology|2023Cited by 227
siRNA Delivery with Chitosan: Influence of Chitosan Molecular Weight, Degree of Deacetylation, and Amine to Phosphate Ratio on in Vitro Silencing Efficiency, Hemocompatibility, Biodistribution, and in Vivo EfficacyMohamad‐Gabriel Alameh, Michael D. Buschmann, Marc Lavertu et al.|Biomacromolecules|2017Cited by 135
A multivalent mRNA-LNP vaccine protects against <i>Clostridioides difficile</i> infectionMohamad‐Gabriel Alameh, Joseph P. Zackular, Alexa Semon et al.|Science|2024Cited by 73